Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 16/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3633585 | 0.78 | QPCT (1.00) | QPCTKMT2ASMN1; SMN2GAALMNA | |
| SCHEMBL8179678 | 0.78 | QPCT (0.77) | QPCTKMT2ASMN1; SMN2GAALMNA | |
| SCHEMBL11892032 | 0.73 | QPCT (0.68) | QPCTKMT2ASMN1; SMN2GAALMNA | |
| SCHEMBL3635255 | 0.73 | QPCT (0.68) | QPCTKMT2ASMN1; SMN2GAALMNA | |
| SCHEMBL13202855 | 0.71 | QPCT (0.51) | QPCT | |
| SCHEMBL22753601 | 0.70 | QPCT (0.46) | QPCT | |
| SCHEMBL30428818 | 0.69 | CYP1A2 (0.51) | QPCTKMT2ASMN1; SMN2KDM4ELMNA | |
| SCHEMBL22753645 | 0.69 | QPCT (0.47) | QPCT | |
| SCHEMBL14464628 | 0.68 | CHRM2 (0.53) | QPCTKMT2A | |
| SCHEMBL3628902 | 0.68 | QPCT (1.00) | QPCTKMT2ASMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019022600-A1 | TREATING PATHOLOGICAL CONDITIONS BY DIRECT AND INDIRECT TARGETING OF SIRPA - CD47 INTERACTION | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) | 2019-01-31 | — | — | WO | disclosed |